Found 4 clinical trials
Trial of Pembrolizumab in Metastatic Castration Resistant Prostate Cancer
PERSEUS1 is an open-label, single arm, phase II trial evaluating the efficacy of Pembrolizumab in metastatic castration resistant prostate cancer (mCRPC) patients (Part A) with a biomarker enrichment stage (Part B) if efficacy is shown in part A.
- 0 views
- 24 Jan, 2021
- 1 location
A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer
This is a randomized, open-label, three-arm, phase 3 study in men with biochemically recurrent prostate cancer and PSA doubling time ≤ 9 months at the time of study entry.
- 498 views
- 27 May, 2022
- 56 locations
Luteinizing Hormone-releasing Hormone Analogue and Enzalutamide +/- Zoledronic Acid in Prostate Cancer Patients (BonEnza)
-releasing hormone (LHRH) analogue with the use of Whole Boby (WB) DW-MRI.
- 109 views
- 02 Mar, 2022
- 1 location
Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
The purpose of this study is to determine what effects (good and bad) cabozantinib has in treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). The hypothesis for this trial is that cabozantinib has anti-tumor activity in a molecularly-selected group of patients with CRPC.
- 0 views
- 21 Apr, 2022
- 1 location